亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Anti-KLK8

總結: Kallikrein-8 as an early biomarker for the prediction and diagnosis of Alzheimer`s disease – even of precursor stages long before clinical symptoms appear.

技術優勢: First-in-class therapy approach for AD
For the treatment and prevention of AD
Biomarker for predicting and diagnosing AD – even precursor stages of AD long before clinical symptoms appear
Molecular mode of action largely deciphered

技術應用: KLK8 is a potential (early) biomarker for the diagnosis of for Alzheimer’s disease. Antibody-mediated inhibition of KLK8 is a promising therapeutic approach against for Alzheimer’s disease.

詳細技術說明: Four weeks of KLK8 inhibition in a moderate disease stage is sufficient to mitigate multiple features of Alzheimer’s pathology in mice without causing any adverse reactions. Cerebral KLK8 blockade reduces amyloid β (Aβ) pathology by impeding amyloidogenic amyloid-precursor-protein (APP) processing, facilitating Aβ clearance across the blood-brain-barrier and boosting microglial Aβ phagocytosis and autophagy, resulting in decreased Aβ plaque burden.
KLK8 inhibition further attenuates tau pathology by suppressing tau phosphorylation signaling and subsequent tau hyperphosphorylation.

分類: - international:
A61K39/395; A61P25/28; C07K16/40; G01N33/53
- cooperative:
A61K39/395; A61P25/28; C07K16/40; A61K2039/505; A61K2039/54; A61K9/51; C07K2317/76

欲了解更多信息，請點擊這裡